The STEP UP trials revealed that a 7.2 mg dose of semaglutide led to greater weight loss than the currently approved 2.4 mg dose. Nearly half of participants lost 20% or more of their body weight, while also improving metabolic health. Side effects were mostly mild and temporary. Researchers say this could reshape obesity treatment if confirmed in longer-term studies.
The STEP UP trials revealed that a 7.2 mg dose of semaglutide led to greater weight loss than the currently approved 2.4 mg dose. Nearly half of participants lost 20% or more of their body weight, while also improving metabolic health. Side effects were mostly mild and temporary. Researchers say this could reshape obesity treatment if confirmed in longer-term studies. The STEP UP trials revealed that a 7.2 mg dose of semaglutide led to greater weight loss than the currently approved 2.4 mg dose. Nearly half of participants lost 20% or more of their body weight, while also improving metabolic health. Side effects were mostly mild and temporary. Researchers say this could reshape obesity treatment if confirmed in longer-term studies.